Obesity trials recruiting in California

All Obesity trials nationally

Cities in California

Recruiting trials in California

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Irvine, San Diego, Walnut Creek
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Lake Forest, Long Beach, Montclair, Norco
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: Greenbrae, Huntington Park, Rolling Hills Estates, Walnut Creek
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Lynwood, Rolling Hills Estates, Sacramento
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · California: Loma Linda, Los Angeles, Orange, Oxnard
• A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
  NCT07639021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · California: Costa Mesa, Los Angeles
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · California: San Dimas, San Ramon
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Walnut Creek
• A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
  NCT07566390 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · California: Glendale
• A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
  NCT07710768 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · California: Cypress
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female) · California: Escondido
• A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
  NCT07395687 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · California: Cypress
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Escondido, La Mesa, Lincoln, Loma Linda
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Alhambra, Beverly Hills, Chula Vista, Concord
• A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
  NCT07291232 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · California: Anaheim
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · California: Escondido, Fountain Valley, La Jolla, Lake Forest
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Canoga Park, Escondido, Greenbrae, Long Beach
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Escondido, Fountain Valley, Palm Springs, Rolling Hills Estates
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Long Beach, Los Alamitos, Riverside
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Irvine, La Jolla, La Mesa, Rolling Hills Estates
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: Santa Ana
• A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
  NCT06924320 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: Cypress
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Banning, Chula Vista, Covina, Gardena
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Banning, Chula Vista, Covina, Gardena
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · California: Oxnard
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
  NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Huntington Beach, Thousand Oaks
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · California: Los Angeles, Montebello, Tustin
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · California: Canoga Park, Fountain Valley, Garden Grove, Lomita
• A Study of Pitolisant in Patients With Prader-Willi Syndrome
  NCT06366464 · Phase: Phase 3 · Ages: 6 Years and older · Sex: All (male and female) · California: Los Angeles, Sacramento, San Diego
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
  NCT06439277 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · California: Los Angeles, Sacramento
• A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
  NCT07724340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · California: Anaheim
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Escondido
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
  NCT07675590 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · California: Chula Vista
• A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
  NCT07446439 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · California: Los Angeles, San Diego, San Jose
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · California: Apple Valley, Covina, Huntington Beach, La Mesa
• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
  NCT07511205 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · California: Glendale
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: Greenbrae, Huntington Park, Rolling Hills Estates, Walnut Creek
• A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
  NCT07013643 · Phase: Phase 1 · Ages: 35 Years to 75 Years · Sex: Female · California: Glendale
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · California: Fountain Valley, Fremont, Los Angeles, Northridge
• A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
  NCT07723833 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · California: Glendale
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Canoga Park, Escondido, Modesto, Sacramento
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · California: Anaheim, Los Alamitos, Walnut Creek
• A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant
  NCT04453072 · Phase: Not applicable (e.g. observational or device study) · Ages: 13 Years to 30 Years · Sex: All (male and female) · California: Los Angeles
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · California: West Hills
• A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
  NCT07441252 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Canoga Park, Escondido, Rialto, San Diego
• AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
  NCT07503210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Walnut Creek
• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
  NCT07533175 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Escondido, Lomita, Walnut Creek
• AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571005 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: San Diego
• AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07509307 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Escondido, Lancaster, Palm Springs
• Addressing Diabetes by Elevating Access to Nutrition
  NCT05228860 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · California: Concord
• An Online Intuitive Eating Program for Pregnant Women With Obesity to Support Well-Being
  NCT07792837 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · California: San Diego
• Avoid and Resist Strategies for Weight Management
  NCT05143931 · Phase: Not applicable (e.g. observational or device study) · Ages: 14 Years and older · Sex: All (male and female) · California: Los Angeles
• Behavioral Approach for Latinas Addressing Nutrition, Cravings, and Eating Patterns to Prevent Type 2 Diabetes
  NCT07478263 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 55 Years · Sex: Female · California: La Jolla
• Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients
  NCT04997473 · Phase: Not applicable (e.g. observational or device study) · Ages: 13 Years to 30 Years · Sex: All (male and female) · California: Los Angeles
• Benefits of Endoscopic Bariatric Procedures
  NCT05514288 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: Los Angeles
• BrainWeighve App Feasibility Study
  NCT05530538 · Phase: Not applicable (e.g. observational or device study) · Ages: 14 Years to 21 Years · Sex: All (male and female) · California: Los Angeles
• Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
  NCT05419726 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · California: Los Angeles
• CHIME: Comparing Health Interventions for Maternal Equity
  NCT06724172 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · California: Palo Alto
• Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
  NCT05082519 · Phase: Phase 2 · Ages: 7 Years to 25 Years · Sex: All (male and female) · California: Los Angeles, Orange, San Francisco
• Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
  NCT07090005 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years to 65 Years · Sex: All (male and female) · California: Los Angeles
• Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
  NCT06934655 · Phase: Phase 3 · Ages: 12 Years to 18 Years · Sex: All (male and female) · California: Los Angeles
• Early vs. Late Time-Restricted Eating in Adolescents With Obesity (EL TREA)
  NCT05740254 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 21 Years · Sex: All (male and female) · California: Los Angeles
• Effects of Watermelon or Low-fat Cookie Consumption on Wellness
  NCT06323070 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: All (male and female) · California: San Diego
• Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
  NCT04913064 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years and older · Sex: Female · California: Duarte
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · California: Escondido, Gardena, La Jolla, Modesto
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Fountain Valley, Santa Ana, Spring Valley, Walnut Creek
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: Irvine, Lincoln, Northridge
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Northridge, Oceanside
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Escondido, La Mesa, Montclair, Northridge
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · California: Escondido, Toluca Lake
• Efficacy of Using Mobile Health Applications for Health
  NCT05589155 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · California: San Diego
• Efficacy of mHealth Applications in Weight Management in a Population Affected by Overweight or Obesity
  NCT05726942 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · California: San Diego
• Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
  NCT05279729 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · California: San Diego
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Palm Springs, Rialto, Rolling Hills Estates, San Diego
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · California: Covina, Huntington Park, La Mesa, Lake Forest
• Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
  NCT07607587 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · California: Walnut Creek
• Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
  NCT07225816 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · California: Cypress
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Fountain Valley, Long Beach, Montclair, Riverside
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
  NCT07684144 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Canoga Park, Cerritos, Chula Vista, Pomona
• FEAST Perinatal Support Program Intervention
  NCT06715787 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · California: Los Angeles
• Family Intervention to Prevent Childhood Obesity
  NCT05606731 · Phase: Not applicable (e.g. observational or device study) · Ages: 2 Years and older · Sex: All (male and female) · California: Los Angeles
• Family, Responsibility, Education, Support, and Health for Food Responsiveness
  NCT06207110 · Phase: Not applicable (e.g. observational or device study) · Ages: 7 Years to 12 Years · Sex: All (male and female) · California: La Jolla
• Feasibility and Colorectal Benefits of Pulses Supplementation
  NCT06032104 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 80 Years · Sex: All (male and female) · California: Sacramento
• Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center
  NCT06897982 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Los Angeles
• Food FARMacia: Reducing Childhood Obesity in Households With Food Insecurity
  NCT06051591 · Phase: Not applicable (e.g. observational or device study) · Ages: 6 Months and older · Sex: All (male and female) · California: Stanford
• Food Prescriptions to Promote Affordable Diets
  NCT05309395 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · California: Pasadena
• Fructose Intestinal Gluconeogenesis
  NCT07209202 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 55 Years · Sex: All (male and female) · California: Vallejo
• Inflammation, Diabetes, Ethnicity and Obesity Cohort
  NCT03022682 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · California: San Francisco
• Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
  NCT05165706 · Phase: Not applicable (e.g. observational or device study) · Ages: 35 Years to 65 Years · Sex: All (male and female) · California: Stanford
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
  NCT07226765 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Northridge, Rolling Hills Estates
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
  NCT07225686 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Northridge, Rolling Hills Estates
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · California: Beverly Hills, Covina, Huntington Beach, Inglewood
• Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
  NCT06783751 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · California: Orange, San Diego
• Metabolic Responses to Bariatric Surgery
  NCT02024542 · Phase: Not specified · Ages: 18 Years to 55 Years · Sex: All (male and female) · California: Sacramento
• Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
  NCT06230510 · Phase: Not applicable (e.g. observational or device study) · Ages: 23 Months to 48 Months · Sex: All (male and female) · California: Oakland
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · California: Anaheim, Beverly Hills, Los Alamitos, Northridge
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · California: Anaheim, Beverly Hills, Los Alamitos, Northridge
• Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
  NCT05833217 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · California: Palo Alto
• Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers
  NCT06891352 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · California: La Jolla
• Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
  NCT04721873 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · California: La Jolla